Evidence‑Based Management of Autoimmune Uveitis

Anterior Uveitis – First‑Line Therapy

Initiate topical corticosteroid (prednisolone acetate 1 % or dexamethasone) every 1–2 hours while awake, then taper according to clinical response; low‑dose regimens (≤ 3 drops daily) carry a low risk of cataract formation. Grade B evidence. 1
High‑dose topical corticosteroid regimens (> 3 drops daily) increase cataract risk independent of active inflammation. Grade B evidence. 1

Methotrexate is the preferred first‑line systemic immunosuppressive agent for non‑anterior non‑infectious uveitis, with Grade B evidence for maintaining and improving visual acuity. [2][3]
Systemic corticosteroids must be combined with an immunosuppressive agent; monotherapy is not recommended. Grade B evidence. 2

Escalate to biologic therapy when inflammation is inadequately controlled by methotrexate or other conventional DMARDs, when disease remains corticosteroid‑dependent, or when first‑line agents are intolerable. Grade B evidence. [3][4]
Adalimumab has Grade A evidence (highest quality) for reducing flares and preventing vision loss in adult patients with non‑anterior non‑infectious uveitis. [3][4]
In JIA‑associated anterior uveitis, combination therapy with adalimumab plus methotrexate reduces treatment failure by approximately 75 % compared with methotrexate alone. Grade A evidence. [3][4]
Infliximab shows Grade B/C evidence for efficacy in non‑infectious uveitis, particularly in Behçet’s disease. [3][4]
Etanercept lacks evidence of efficacy for non‑infectious uveitis and is not recommended. Grade B evidence. [3][4]

Mycophenolate mofetil provides controlled inflammation in roughly 71 % of posterior uveitis cases, with efficacy comparable to methotrexate; Grade C evidence. [3][4]
Azathioprine has Level IB evidence for treating posterior segment inflammation but is associated with higher discontinuation rates due to side effects compared with methotrexate and mycophenolate. Level IB evidence. [3][4]
Interferon‑α2a demonstrates Grade B evidence for effectiveness in non‑anterior uveitis. [3][4]

Ophthalmologic follow‑up frequency should be individualized to disease severity and coordinated with an expert ophthalmologist. Grade B evidence. [1][2]
Higher anterior chamber cell grades correlate with a dose‑dependent increase in vision‑loss risk. Grade B evidence. 2
Regular monitoring is required to detect complications such as glaucoma, macular edema, cataract, hypotony, and retinal detachment. Grade B evidence. 2

Require at least 2 years of inactive uveitis before discontinuing methotrexate. Grade B evidence. [1][2]
Require 2 years of inactivity without topical steroids before tapering systemic immunosuppression. Grade B evidence. [1][2]
The majority of patients experience relapse within 24 months after stopping therapy; the highest relapse risk occurs in the first year. Grade B evidence. [1][2]
After cessation, patients should be examined by an ophthalmologist at least every 3 months for the first year and continue surveillance for ≥ 3 years off all treatment to detect early recurrence. Grade B evidence. [1][2]

Children with JIA often develop chronic, insidious anterior uveitis that may be asymptomatic; routine screening is essential regardless of symptom presence. Grade B evidence. 5
Systemic therapy for JIA‑associated uveitis should preferentially use adalimumab combined with methotrexate, which is superior to methotrexate alone in preventing treatment failure. Grade A evidence. [3][4]

The American College of Rheumatology recommends that patients with moderate to severe eye pain, photophobia, blurred vision, or decreased visual acuity should be referred urgently to an ophthalmologist with experience in inflammatory eye disease 6
The presence of posterior or intermediate uveitis indicates a higher risk of vision-threatening complications and requires urgent management 6
Episcleritis can be managed less urgently, but escleritis requires urgent referral similar to uveitis 6

The European League Against Rheumatism recommends that topical corticosteroids (preferably prednisolone acetate or dexamethasone) should be initiated immediately as first-line treatment for acute anterior uveitis 7, 8
The American Academy of Ophthalmology suggests that early intensive treatment with close monitoring reduces complications and prevents vision loss in most cases 9, 10
Topical non-steroidal anti-inflammatory drugs (NSAIDs) or systemic NSAIDs have no demonstrated effect as monotherapy but may be used as additional therapy 7

The American College of Rheumatology recommends that patients with posterior, intermediate, or panuveitis require immediate systemic immunosuppression and should never be treated with topical corticosteroids alone 11
Systemic corticosteroids should always be combined with immunosuppressive agents and never used as monotherapy for posterior uveitis 11

The presence of structural damage at diagnosis, macular edema, or optic disc edema requires immediate systemic immunosuppression 6, 7, 10, 12
Hypotony, rubeosis iridis, or inflammation not responding to topical steroids within 3 months also indicate a need for systemic immunosuppression 7, 12

The American Academy of Ophthalmology emphasizes the importance of ruling out infectious causes before initiating immunosuppression to avoid worsening the outcome and causing permanent vision loss 13
Screening for latent or active tuberculosis is essential before starting systemic immunomodulatory therapy 13

Untreated uveitis can cause cataracts, glaucoma, macular edema, retinal detachment, optic nerve damage, and permanent vision loss 6, 9, 12

Regular ophthalmological surveillance is mandatory, with monitoring for at least 3 years after achieving remission to detect early recurrence 11, 13
After discontinuing immunosuppression, patients should be evaluated by an ophthalmologist at least every 3 months for a minimum of 1 year 11, 12, 14